Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Mitochondrial Redox Stress in BV2 Microglia
2026-11-20
Cao and colleagues linked titanium dioxide nanoparticle exposure to mitochondrial oxidative stress, altered fission–fusion balance, metabolic disruption, apoptosis, and autophagy in BV2 microglia. The study’s use of Mito-TEMPO as a mitochondria-targeted antioxidant strengthened the case that mitochondrial ROS participates upstream in the injury cascade. Its integrated design is mechanistically informative, but the findings remain bounded by an immortalized-cell model, material-specific physicochemical behavior, and the interpretive limits of ROS, protein, and metabolomic measurements.
What LNP Comparisons Reveal About COMET
2026-11-20
Published results support COMET as a strong ranking model for reporter-expression performance within the formulation space represented by its training data. They also show why cross-cell generalization, in vitro–in vivo translation, and extension to chemically distinct nucleic-acid cargos remain unresolved.
What Icilin Reveals About Channels and Cell Cycle
2026-11-19
Icilin is documented as a TRPM8 agonist with additional activity at hENaCδ and a separate anti-proliferative phenotype in PC-3 prostate cancer cells. The evidence supports distinct assay-level mechanisms rather than one established pathway connecting channel activation to G1 arrest.
How to Interpret Penfluridol’s Class Label
2026-11-19
Penfluridol is described as a highly potent, first-generation diphenylbutylpiperidine antipsychotic. That wording establishes a broad pharmacological identity, but it does not by itself provide a numerical potency value, define a molecular target, or demonstrate product-specific biological performance.
NHE1, Octanal, and Macrophage Atherosclerosis
2026-11-18
A 2025 mouse-and-macrophage study places NHE1 downstream of octanal–Olfr2 signaling and links the exchanger to calcium-associated oxidative stress, inflammasome activity, foam-cell formation, and plaque progression. The evidence is mechanistically convergent but remains limited to preclinical models and proxy readouts.
How ACL Inhibition Shapes Lipid Metabolism
2026-11-18
BMS-303141 illustrates how inhibition of ATP-citrate lyase can connect a molecular target to cellular lipid synthesis and broader metabolic readouts. The evidence is strongest at the enzyme and cell levels, while mouse outcomes require more cautious interpretation because plasma lipids, glucose, and body weight reflect multiple biological processes.
How PvuII Turns Sequence Into Fragments
2026-11-17
PvuII links recognition of a defined palindromic DNA sequence to blunt-ended fragments and an interpretable gel pattern. The mechanism supports predictable DNA fragment analysis, while product-specific claims about rapid digestion and tracer dyes require separate interpretation from independent performance validation.
How Sivelestat Connects Protease and Inflammation
2026-11-17
Sivelestat sodium salt is documented as a selective leukocyte elastase inhibitor with a reported IC50 of 44 nM and effects spanning biochemical, cellular, and animal inflammation readouts. Interpreting those findings requires separating direct protease inhibition from downstream changes in signaling, leukocyte movement, cytokines, and tissue injury.
How TLR7 Agonism Shapes Innate Signaling
2026-11-16
BBIQ is described as an imidazoquinoline TLR7 agonist with a reported value of 59.1 nM in a human context. The key interpretation is that receptor selectivity, a numerical potency value, and vaccine-adjuvant performance represent different levels of evidence and should not be treated as interchangeable.
How Eltrombopag Maps to Platelet Output
2026-11-16
Eltrombopag is described as a nonpeptide thrombopoietin receptor agonist that acts through c-Mpl. The key interpretive question is how evidence at the receptor or progenitor-cell level relates to the more distal outcome of platelet production, because these endpoints represent different biological claims.
How CAL-101 Links PI3Kδ Blockade to B-Cell Death
2026-11-15
CAL-101, also known as Idelalisib or GS-1101, is described as a selective PI3Kδ inhibitor that connects target engagement with suppression of Akt–mTOR signaling and apoptosis-associated changes in malignant B cells. The key interpretive point is that biochemical inhibition, pathway readouts, and loss of cell viability are related but distinct levels of evidence.
How Darunavir Connects Target to Antiviral Readouts
2026-11-13
Darunavir Ethanolate illustrates why HIV protease inhibition, cellular viral replication, transporter behavior, and oral bioavailability are related but distinct evidence layers. The documented mechanism supports a coherent interpretation of antiviral action while leaving potency, resistance breadth, and product-specific clinical conclusions dependent on their measurement context.
Dual-Targeting CAR-T for Heterogeneous NSCLC
2026-11-13
A preclinical study examines whether a dual-targeting CAR-T design can address antigen heterogeneity in non-small cell lung cancer while preserving functional and metabolic features associated with sustained T-cell activity.
How EGFR Kinase Inhibition Changes Cell Signaling
2026-11-12
A biochemical EGFR inhibition value describes direct kinase activity, whereas cellular autophosphorylation and apoptosis represent downstream biological consequences. The reported measurements support a mechanistic connection between EGFR blockade and altered survival signaling, but they do not establish uniform effects across all cancer models.
When Context Changes a Metabolic Result
2026-11-12
A chemical identity, an analytical signal, and a biological outcome answer different questions. Comparing sodium 3-oxobutanoate documentation with a deuterium-labeled degarelix study shows why isotope patterns and synthetic yields cannot be interpreted as evidence of metabolic or clinical efficacy.